<p>Caris Life Sciences, Inc. (NASDAQ:CAI - 获取免费报告) 在周二达到了新的 52 周低点。该股票最低交易价格为 20.35 美元，最后交易价格为 20.35 美元，成交量为 28483 股。该股票之前的收盘价为 20.62 美元。</p>
<p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>CAI 已成为几份研究报告的主题。Evercore 在 1 月 5 日的研究报告中对 Caris Life Sciences 的股票设定了 38.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Caris Life Sciences 股票的 &#34;卖出 (d)&#34; 评级。Wall Street Zen 在 1 月 17 日的研究报告中将 Caris Life Sciences 的股票评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。Canaccord Genuity Group 在 12 月 22 日的报告中将 Caris Life Sciences 的股票目标价从 28.00 美元上调至 30.00 美元，并给予该股票 &#34;持有&#34; 评级。最后，Robert W. Baird 在周二的研究报告中开始覆盖 Caris Life Sciences 的股票。他们对该公司的评级为 &#34;跑赢大盘&#34;，目标价为 26.00 美元。一位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Caris Life Sciences 的平均评级为 &#34;持有&#34;，平均目标价为 31.33 美元。</p>
<p><strong>获取我们最新的 CAI 股票分析</strong></p>
<h2>Caris Life Sciences 价格表现</h2>
<p>该公司有 50 日简单移动平均线为 25.80 美元。公司的流动比率为 9.93，速动比率为 9.36，债务与股本比率为 0.79。该公司的市值为 58.6 亿美元，市盈率为-45.13。</p>
<h2>Caris Life Sciences 的内部活动</h2>
<p>在其他新闻中，内部人士 Luke Thomas Power 于 12 月 11 日星期四出售了 62,250 股 Caris Life Sciences 股票。股票以平均价格 26.58 美元出售，总价值为 1,654,605.00 美元。出售完成后，内部人士在公司持有 99,571 股，价值为 2,646,597.18 美元。该交易使其持股减少了 38.47%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此链接获取。</p>
<h2>Caris Life Sciences 的机构交易</h2>
<p>一些大型投资者最近买入和卖出了 CAI 的股票。MetLife Investment Management LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 84.0%。MetLife Investment Management LLC 现在拥有 1,654 股该公司的股票，价值 45,000 美元，在此期间又购买了 755 股。Global Retirement Partners LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 99,900.0%。Global Retirement Partners LLC 现在拥有 1,000 股该公司的股票，价值 27,000 美元，在上个季度又购买了 999 股。Olistico Wealth LLC 在第四季度购买了 Caris Life Sciences 的新股份，价值 31,000 美元。新泽西州警察和消防员退休系统在第四季度将其在 Caris Life Sciences 的持股增加了 15.0%。新泽西州警察和消防员退休系统现在拥有 11,932 股该公司的股票，价值 322,000 美元，在上个季度又购买了 1,560 股。最后，PEAK6 LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 6.9%。PEAK6 LLC 现在拥有 24,800 股该公司的股票，价值 669,000 美元，在上个季度又购买了 1,600 股。</p>
<h2>关于 Caris Life Sciences</h2>
<p>(获取免费报告)</p>
<p>Caris Life Sciences NASDAQ: CAI 是一家分子科学公司，专注于推动肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，支持肿瘤科医生的治疗决策。</p>
<p>Caris 提供基于实验室的诊断测试和相关的解释报告，将高通量测序和其他分子技术与生物信息学分析相结合。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票超过 Caris Life Sciences</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发布大胆的特斯拉预测</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><em>此即时新闻提醒是由叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
<p>在你考虑投资 Caris Life Sciences 之前，你会想听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Caris Life Sciences 并不在名单上。</p>
<p>虽然 Caris Life Sciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国医疗保健供应商 ETF - iShares

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Caris Life Sciences (NASDAQ:CAI) 达到新的 52 周低点 20.35 美元，交易量为 28,483 股。分析师的评级各不相同，有一项买入、一项持有和一项卖出。价格目标各异，Evercore 为 38.00 美元，Canaccord Genuity 为 30.00 美元。该公司的市值为 58.6 亿美元，市盈率为-45.13。最近的内部交易中，Luke Thomas Power 出售了 62,250 股。Caris 专注于肿瘤学的精准医疗，提供分子分析服务以支持治疗决策</p>

<p>Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $20.35 and last traded at $20.35, with a volume of 28483 shares trading hands. The stock had previously closed at $20.62.</p>
<div class="lb-trans"><p>Caris Life Sciences, Inc. (NASDAQ:CAI - 获取免费报告) 在周二达到了新的 52 周低点。该股票最低交易价格为 20.35 美元，最后交易价格为 20.35 美元，成交量为 28483 股。该股票之前的收盘价为 20.62 美元。</p>
</div><p>Get <strong>Caris Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Caris Life Sciences</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>CAI has been the topic of several research reports. Evercore set a $38.00 price target on shares of Caris Life Sciences in a research report on Monday, January 5th. Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Caris Life Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, January 17th. Canaccord Genuity Group boosted their price target on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, December 22nd. Finally, Robert W. Baird assumed coverage on shares of Caris Life Sciences in a research note on Tuesday. They set an &#34;outperform&#34; rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Caris Life Sciences has an average rating of &#34;Hold&#34; and an average price target of $31.33.</p>
<div class="lb-trans"><p>CAI 已成为几份研究报告的主题。Evercore 在 1 月 5 日的研究报告中对 Caris Life Sciences 的股票设定了 38.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Caris Life Sciences 股票的 &#34;卖出 (d)&#34; 评级。Wall Street Zen 在 1 月 17 日的研究报告中将 Caris Life Sciences 的股票评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。Canaccord Genuity Group 在 12 月 22 日的报告中将 Caris Life Sciences 的股票目标价从 28.00 美元上调至 30.00 美元，并给予该股票 &#34;持有&#34; 评级。最后，Robert W. Baird 在周二的研究报告中开始覆盖 Caris Life Sciences 的股票。他们对该公司的评级为 &#34;跑赢大盘&#34;，目标价为 26.00 美元。一位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Caris Life Sciences 的平均评级为 &#34;持有&#34;，平均目标价为 31.33 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on CAI</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 CAI 股票分析</strong></p>
</div><h2>Caris Life Sciences Price Performance</h2>
<div class="lb-trans"><h2>Caris Life Sciences 价格表现</h2>
</div><p>The firm has a 50-day simple moving average of $25.80. The company has a current ratio of 9.93, a quick ratio of 9.36 and a debt-to-equity ratio of 0.79. The company has a market cap of $5.86 billion and a P/E ratio of -45.13.</p>
<div class="lb-trans"><p>该公司有 50 日简单移动平均线为 25.80 美元。公司的流动比率为 9.93，速动比率为 9.36，债务与股本比率为 0.79。该公司的市值为 58.6 亿美元，市盈率为-45.13。</p>
</div><h2>Insider Activity at Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的内部活动</h2>
</div><p>In other news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $26.58, for a total value of $1,654,605.00. Following the completion of the sale, the insider owned 99,571 shares in the company, valued at $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Luke Thomas Power 于 12 月 11 日星期四出售了 62,250 股 Caris Life Sciences 股票。股票以平均价格 26.58 美元出售，总价值为 1,654,605.00 美元。出售完成后，内部人士在公司持有 99,571 股，价值为 2,646,597.18 美元。该交易使其持股减少了 38.47%。该交易已在与 SEC 的法律文件中披露，相关信息可通过此链接获取。</p>
</div><h2>Institutional Trading of Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的机构交易</h2>
</div><p>A number of large investors have recently bought and sold shares of CAI. MetLife Investment Management LLC raised its position in shares of Caris Life Sciences by 84.0% in the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company's stock valued at $45,000 after purchasing an additional 755 shares during the period. Global Retirement Partners LLC grew its position in shares of Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company's stock valued at $27,000 after purchasing an additional 999 shares in the last quarter. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences during the 4th quarter valued at $31,000. Police &amp; Firemen s Retirement System of New Jersey lifted its holdings in Caris Life Sciences by 15.0% during the 4th quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 11,932 shares of the company's stock worth $322,000 after purchasing an additional 1,560 shares in the last quarter. Finally, PEAK6 LLC grew its holdings in Caris Life Sciences by 6.9% during the 4th quarter. PEAK6 LLC now owns 24,800 shares of the company's stock valued at $669,000 after buying an additional 1,600 shares in the last quarter.</p>
<div class="lb-trans"><p>一些大型投资者最近买入和卖出了 CAI 的股票。MetLife Investment Management LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 84.0%。MetLife Investment Management LLC 现在拥有 1,654 股该公司的股票，价值 45,000 美元，在此期间又购买了 755 股。Global Retirement Partners LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 99,900.0%。Global Retirement Partners LLC 现在拥有 1,000 股该公司的股票，价值 27,000 美元，在上个季度又购买了 999 股。Olistico Wealth LLC 在第四季度购买了 Caris Life Sciences 的新股份，价值 31,000 美元。新泽西州警察和消防员退休系统在第四季度将其在 Caris Life Sciences 的持股增加了 15.0%。新泽西州警察和消防员退休系统现在拥有 11,932 股该公司的股票，价值 322,000 美元，在上个季度又购买了 1,560 股。最后，PEAK6 LLC 在第四季度将其在 Caris Life Sciences 的持股增加了 6.9%。PEAK6 LLC 现在拥有 24,800 股该公司的股票，价值 669,000 美元，在上个季度又购买了 1,600 股。</p>
</div><h2>About Caris Life Sciences</h2>
<div class="lb-trans"><h2>关于 Caris Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.</p>
<div class="lb-trans"><p>Caris Life Sciences NASDAQ: CAI 是一家分子科学公司，专注于推动肿瘤学中的精准医学。该公司开发并提供全面的分子分析服务，旨在识别 DNA、RNA 和蛋白质模式中的可操作生物标志物。其临床服务旨在通过根据肿瘤生物学将患者与靶向疗法、免疫疗法和相关临床试验匹配，支持肿瘤科医生的治疗决策。</p>
</div><p>Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.</p>
<div class="lb-trans"><p>Caris 提供基于实验室的诊断测试和相关的解释报告，将高通量测序和其他分子技术与生物信息学分析相结合。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Caris Life Sciences</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Caris Life Sciences</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发布大胆的特斯拉预测</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Caris Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Caris Life Sciences 吗？</h2>
</div><p>Before you consider Caris Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Caris Life Sciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caris Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Caris Life Sciences 并不在名单上。</p>
</div><p>While Caris Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Caris Life Sciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Caris Life Sciences (NASDAQ:CAI) Sets New 12-Month Low  - Here's What Happened

Market Beat

美国医药设备 ETF - iShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

基因免疫&健康关怀 ETF - iShares

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

医疗业 ETF - SPDR

Caris Life Sciences

2 倍做多纳斯达克生物技术 ETF - ProShares

Caris Life Sciences（纳斯达克代码：CAI）创下新的 12 个月低点 - 以下是发生的情况